Novavax Inc.’s shares plunged nearly 20 percent in premarket trading on May 10 due to uncertainty over global demand for the company’s COVID-19 vaccine following a slow start to deliveries.
COVID vaccine makers shift focus to boosters
AstraZeneca, Biopharma Companies, BNT162b2 (Pfizer and BioNTech), Coronavirus Vaccines, COVID vaccine mandates, COVID-19 booster shots, COVID-19 shots, COVID-19 Vaccines, CureVac, GlaxoSmithKline, Janssen, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, Mixing & Matching Covid-19 Vaccines, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Novavax, R&D, Therapeutics, Vaccines, Vaxzevria (previously COVID-19 Vaccine AstraZeneca)COVID-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months.
Novavax shared positive initial results from the Phase I/II clinical study of the company’s proposed combination vaccine for COVID-19.
Novavax Inc. announced the launch of the biotechnology company’s global unbranded ‘We Do Vaccines’ and ‘Know Our Vax’ programs, educational efforts aimed to help protect the health of people everywhere in the fight against COVID-19 and other deadly infectious diseases, such as influenza.
The CEO of Maryland-based Novavax believes U.S. Emergency Use Authorization (EUA) for the company’s protein-based COVID-19 vaccine could happen “within weeks.”
Novavax Inc. said on February 10 the company’s two-dose vaccine was 80% effective against COVID-19 in a late-stage trial testing the shot in teens aged 12 to 17 years.
Novavax Inc. delivered just a small fraction of the 2 billion COVID-19 shots the company plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income countries such as the Philippines, public officials involved in their government’s vaccine rollouts told Reuters.
Novavax, after delays, files for U.S. authorization of COVID-19 vaccine
Adults, Business, COVAX Facility, Covid-19 Data, COVID-19 Vaccines, Covid-19 Variants, Delta Variant (B.1.617.2; India), Emergency Use Authorization (EUA), Facilities/Sites/Manufacturing, FDA, Mexico, Novavax, Omicron (B.1.1.529) (South Africa), R&D, Serum Institute of India, United Kingdom, United States, World Health OrganizationNovavax Inc. filed for emergency use authorization of the company’s COVID-19 vaccine for U.S. adults, a long-awaited step following months of struggles with development and manufacturing problems.
J&J Suffers New Warning Label, Woodcock: “Most People are Going to Get COVID”
Adverse Events, Bleeding Disorders, Cannabinoids, Chronic Immune Thrombocytopenia (ITP), Coronavirus Disease (COVID-19) Pandemic, COVID-19 Infections, Dr. Anthony Fauci (Director), Endemic, FDA, FDA Commissioner, Immunogenicity Data, Janssen, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, National Institute of Allergy and Infectious Diseases (NIAID), Novavax, Omicron (B.1.1.529) (South Africa), South KoreaThe U.S. Food and Drug Administration added another warning to the regulatory agency’s fact sheet for Johnson & Johnson’s COVID-19 vaccine. In other news, as the Omicron variant rips through the United States, top health officials have noted that the variant is so contagious that if you come into contact with it, you are likely to catch it.
The 2022 virtual J.P. Morgan Healthcare Conference got off to a roaring start with deal announcements and plans to drive biopharma companies through the year.